Loading
Inato
Inato is a global technology company based in Paris that operates an AI-powered platform designed to connect pharmaceutical sponsors, clinical research sites, and patients. The platform aims to accelerate and diversify access to clinical trials, making medical research more accessible and inclusive. Inato's mission focuses on bringing life-changing treatments to communities that are often underrepresented in drug trials. The platform integrates several key functions, including trial planning and site selection, AI-powered patient pre-screening, and a free marketplace for research sites. This allows sponsors to access diverse patient populations and enables clinical research sites to showcase their capabilities without any fees. Inato has been recognized as one of Fast Company’s Most Innovative Companies of 2024 for its efforts in improving patient representation in drug trials. The company has raised $20 million in funding to further its vision of ensuring clinical research reaches every patient, regardless of location.
Funding
Every round, secondary, debt facility or acquisition involving Inato that Lounge tracks, newest first.
No rounds recorded yet.
In the news
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$3M